About Index Trending news
Analyze
Top 50 Pricing
Juno Therapeutics, Inc.

Juno Therapeutics, Inc.

Work at Juno Therapeutics, Inc.? Add yourself to this profile

Juno Therapeutics, Inc.

Juno Therapeutics, a clinical-stage company, develops immunotherapies for thetreatment of cancer.

Elsewhere

Alexa global traffic share

Employees

Team size

200+
Locations
HQ
GeekWire

Mayor Bill de Blasio wanted Juno Therapeutics to move to New York — here’s why it’s saying in Seattle

City life Health
GeekWire

Study of Juno Therapeutics cancer treatment shows high rates of remission, possible promise for other drugs

GeekWire

Juno Therapeutics sued for securities fraud following patient death

GeekWire

Juno posts loss as it amps up R&D spending for cancer trials

Health Earnings
$10,000,000
GeekWire

The $10 million molecule: Juno Therapeutics’ acquisition of RedoxTherapies could improve cancer treatment

Xconomy

FDA Lets Juno Jump Back Into T-Cell Trial, Minus One Chemo Drug

GeekWire , Xconomy

FDA suspends Juno Therapeutics clinical trial for leukemia treatment after 2 patient deaths

The Motley Fool

Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.

The Motley Fool

Why Juno Therapeutics Soared 10.5% Today

The Motley Fool

Better Buy: Juno Therapeutics vs. bluebird bio

The Motley Fool

8 Figures That Sum Up Juno Therapeutics' First Quarter

Health Earnings
The Motley Fool

Big Drugmakers Were Key to Juno Therapeutics' Q1 Performance

The Motley Fool

Better Buy: Juno Therapeutics vs. Incyte

Health Stock markets Earnings
The Motley Fool

Better Buy: Inovio Pharmaceuticals Inc. vs. Juno Therapeutics

The Motley Fool

Why Juno Therapeutics Shares Soared 29.2% in February

Health Stock markets Earnings
The Motley Fool

Why Juno Therapeutics Shares Are Flying High Today

Stock markets
The Motley Fool

Juno Therapeutics Shows Improvement in Q4

Stock markets
The Motley Fool

Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today

Stock markets
The Motley Fool

Here's Why Juno Therapeutics Dropped 37% in January

The Motley Fool

Why Juno Therapeutics Dropped by 10% on Tuesday

Stock markets Health